Glenmark Pharmaceuticals Inc., USA (Glenmark) and Glenmark Pharmaceuticals Limited have reached a settlement agreement with Pfizer Inc., PF Prism C.V., and PF Prism IMB B.V. (Pfizer) for Axitinib Tablets, 1 mg and 5 mg, the generic version of their Inlyta®1 Tablets, 1 mg and 5 mg. Glenmark had previously announced it received tentative approval by the United States Food & Drug Administration (U.S. FDA) for their generic Axitinib Tablets, 1 mg and 5 mg on November 30, 2020.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.27 USD | -0.19% | +3.34% | -8.75% |
Apr. 24 | Pfizer Keeps Q2 Dividend at $0.42 a Share, Payable June 14 to Holders of Record May 10 | MT |
Apr. 24 | Pfizer Inc. Declares Second-Quarter 2024 Dividend, Payable on June 14, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.75% | 149B | |
+25.61% | 660B | |
+25.87% | 562B | |
-5.24% | 358B | |
+16.49% | 322B | |
+8.28% | 297B | |
+7.09% | 219B | |
-9.12% | 196B | |
+5.01% | 199B | |
-5.21% | 146B |
- Stock Market
- Equities
- PFE Stock
- News Pfizer, Inc.
- Glenmark Pharmaceuticals Reaches Settlement Agreement with Pfizer for Axitinib Tablets, 1 mg and 5 mg